Immix Biopharma, Inc.
IMMX
$2.87
$0.176.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.77% | 15.65% | 58.80% | 21.99% | 63.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.85% | -16.23% | -7.23% | 63.47% | 26.39% |
| Operating Income | -42.85% | 16.23% | 7.23% | -63.47% | -26.39% |
| Income Before Tax | -50.46% | 14.83% | 6.72% | -64.59% | -22.38% |
| Income Tax Expenses | -13.59% | 11.36% | 33.33% | 63.24% | 63.49% |
| Earnings from Continuing Operations | -50.31% | 14.79% | 6.66% | -64.58% | -22.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -100.00% | -- | -41.36% |
| Net Income | -50.76% | 13.62% | 5.45% | -67.01% | -22.84% |
| EBIT | -42.85% | 16.23% | 7.23% | -63.47% | -26.39% |
| EBITDA | -41.73% | 16.87% | 7.56% | -63.40% | -26.30% |
| EPS Basic | -44.76% | 31.86% | 30.34% | -5.47% | 35.83% |
| Normalized Basic EPS | -45.16% | 31.27% | 29.85% | -6.39% | 35.72% |
| EPS Diluted | -44.76% | 31.86% | 30.34% | -5.47% | 35.83% |
| Normalized Diluted EPS | -45.16% | 31.27% | 29.85% | -6.39% | 35.72% |
| Average Basic Shares Outstanding | 4.16% | 26.72% | 35.73% | 58.38% | 91.40% |
| Average Diluted Shares Outstanding | 4.16% | 26.72% | 35.73% | 58.38% | 91.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |